MedCap AB (OSTO:MCAP) Cyclically Adjusted Revenue per Share: kr92.05 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:MCAP MedCap AB OSTO:MCAP
81 GF Score
Price kr519.50
GF Value kr556.75
Valuation Fairly Valued
View Full Analysis

What is MedCap AB Cyclically Adjusted Revenue per Share?

MedCap AB OSTO:MCAP +2.87% 81 Cyclically Adjusted Revenue per Share is kr92.05 as of Mar. 2026. GuruFocus rates OSTO:MCAP with a GF Score™ of 81/100 and a GF Value™ of kr556.75 (Fairly Valued).

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

MedCap AB's adjusted revenue per share for the three months ended in Mar. 2026 was kr37.057. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr92.05 for the trailing ten years ended in Mar. 2026.

During the past 12 months, MedCap AB's average Cyclically Adjusted Revenue Growth Rate was 8.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 7.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 10.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of MedCap AB was 13.60% per year. The lowest was 7.60% per year. And the median was 11.50% per year.

As of today (2026-07-17), MedCap AB's current stock price is kr519.50. MedCap AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was kr92.05. MedCap AB's Cyclically Adjusted PS Ratio of today is 5.64.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of MedCap AB was 7.64. The lowest was 1.62. And the median was 3.61.


MedCap AB  (OSTO:MCAP) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

MedCap AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=519.50/92.05
=5.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of MedCap AB was 7.64. The lowest was 1.62. And the median was 3.61.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


MedCap AB Cyclically Adjusted Revenue per Share Related Terms


MedCap AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for MedCap AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedCap AB Cyclically Adjusted Revenue per Share Chart

MedCap AB Annual Data
Trend Apr16 Apr17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 60.61 72.41 80.86 84.05 90.22

MedCap AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 85.24 86.93 88.32 90.22 92.05

OSTO:MCAP vs ABT, SYK, MDT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, MedCap AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedCap AB Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MedCap AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where MedCap AB's Cyclically Adjusted PS Ratio falls into.


OSTO:MCAP
81GF Score
MedCap AB OSTO:MCAP
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MedCap AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, MedCap AB's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=37.057/133.5600*133.5600
=37.057

Current CPI (Mar. 2026) = 133.5600.

MedCap AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201604 17.616 100.732 23.357
201607 17.773 101.080 23.484
201610 16.570 101.485 21.807
201701 15.214 101.326 20.054
201704 13.995 102.615 18.215
201707 14.023 103.301 18.131
201710 14.819 103.202 19.178
201803 13.605 103.962 17.478
201806 12.917 104.875 16.450
201809 12.319 105.679 15.569
201812 14.056 105.912 17.725
201903 14.854 105.886 18.736
201906 13.858 106.742 17.340
201909 11.886 107.214 14.807
201912 15.682 107.766 19.436
202003 15.288 106.563 19.161
202006 14.578 107.498 18.112
202009 11.851 107.635 14.705
202012 15.332 108.296 18.909
202103 15.039 108.360 18.537
202106 15.772 108.928 19.339
202109 13.662 110.338 16.537
202112 17.417 112.486 20.680
202203 17.755 114.825 20.652
202206 19.187 118.384 21.647
202209 16.310 122.296 17.812
202212 21.814 126.365 23.056
202303 25.644 127.042 26.960
202306 25.974 129.407 26.808
202309 24.527 130.224 25.155
202312 30.706 131.912 31.090
202403 30.978 132.205 31.295
202406 30.634 132.716 30.829
202409 27.617 132.304 27.879
202412 31.753 132.987 31.890
202503 32.902 132.825 33.084
202506 34.713 133.699 34.677
202509 33.433 133.480 33.453
202512 39.389 133.390 39.439
202603 37.057 133.560 37.057

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr92.05 mean?
MedCap AB (OSTO:MCAP) has a Cyclically Adjusted Revenue per Share of kr92.05 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on MedCap AB and its competitors.
Is MedCap AB's Cyclically Adjusted Revenue per Share too high?
MedCap AB's current Cyclically Adjusted Revenue per Share is kr92.05. Overall, MedCap AB has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's Cyclically Adjusted Revenue per Share compare to ABT and SYK?
MedCap AB's Cyclically Adjusted Revenue per Share of kr92.05 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on MedCap AB and its competitors. MedCap AB's current Cyclically Adjusted Revenue per Share is kr92.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
Based on GuruFocus' analysis, MedCap AB (OSTO:MCAP) is currently considered Fairly Valued. The stock's GF Value™ is kr556.75, compared to a current price of kr519.50 — trading 6.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is kr92.05. MedCap AB's overall GF Score™ is 81/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For MedCap AB (OSTO:MCAP), the current Cyclically Adjusted Revenue per Share is kr92.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MedCap AB (OSTO:MCAP) Overvalued in 2026?

Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued. The current stock price of kr519.50 is trading 6.7% below its estimated GF Value™ of kr556.75. GuruFocus considers MedCap AB to be Fairly Valued.

Key valuation signals for OSTO:MCAP:

  • Cyclically Adjusted Revenue per Share: kr92.05
  • GF Value™: kr556.75 vs. price of kr519.50 (6.7% below fair value)
  • GF Score™: 81/100

No single metric tells the full story. See the OSTO:MCAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


MedCap AB Business Description

Other Exchanges MCAPs:UK61MA:Germany
Address Sundbybergsvagen 1, Solna, SWE, 171 73
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
81GF Score

Get the complete analysis for OSTO:MCAP

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr519.50
Price
kr556.75
GF Value